April 11 (Bloomberg) — U.S. officials, defending a decision to release pay data that suggests some eye doctors made millions of dollars from Medicare, say the list should spur physicians to push lower-cost drugs to their patients.
Doctors say they're being unfairly flogged for a system they can't control.
The squabble centers on Roche Holding AG's Lucentis, a $2,000-per-vial injection for a degenerative eye disease in seniors. Because the treatment's cost is included in their reimbursement, eye doctors dominated the list of Medicare's top earners. By listing payments without that explanation, doctors say the government is trying to embarrass and pressure them into switching patients to a lower-cost option.
Continue Reading for Free
Register and gain access to:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
